Vericel Corporation is a biotechnology company that focuses on developing and commercializing innovative, cell-based products for a variety of medical needs
Specializing in regenerative medicine, Vericel primarily addresses the treatment of diseases and conditions affecting the skin and cartilage. Their flagship products are designed to enhance healing and improve patient outcomes, particularly in areas such as sports medicine and burn care. Through its commitment to research and development, Vericel aims to transform the treatment landscape for patients with complex medical needs.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel’s Head of Human Resources since September 2010.
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.
